



PI : Prof. Wen-Ming Hsu

Department of surgery, National Taiwan University
College of Medicine

Experience:

<https://scholars.lib.ntu.edu.tw/cris/rp/rp06222>

Market Needs:

Each year, about 30 children are diagnosed with neuroblastoma (NB) in Taiwan, and there are about 800 cases per year in the United States. Because of the difficulty in the treatment of this disease, the development of new therapeutics is urgent although the market is minor.

Our Technology:

The new drug is an endogenous ligand of the aryl hydrocarbon receptor (AHR). When binding to AHR, the new drug activates the AHR downstream signaling resulting in the upregulation of genes involved in the neural differentiation. Thus, this new therapeutics possesses the ability to inhibit the tumor growth of NB by promoting cancer cell differentiation.

Strength:

By the in vivo test, the inhibitory effect of the new therapeutic on the tumor growth of NB is dominant compared with retinoic acid (RA), a clinical medication used to promote differentiation of NB cells. In addition, the new drug may cause lower side-effects due to its endogenous property.

Competing Products:

Retinoic acid (RA)

Intellectual Properties:

The provisional application for patent has been approved (Application number: 62861516). The patent is pending for this new therapeutics.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw